Opendata, web and dolomites

PANBioRA SIGNED

Personalized And/Or Generalized Integrated Biomaterial Risk Assessment

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 PANBioRA project word cloud

Explore the words cloud of the PANBioRA project. It provides you a very rough idea of what is the project "PANBioRA" about.

panbiora    risk    biomaterial    biomaterials    risks    tools    platform    patient    time    scales    personalized    implantation    health    biomechanical   

Project "PANBioRA" data sheet

The following table provides information about the project.

Coordinator
STEINBEIS 2I GMBH 

Organization address
address: KIENESTRASSE 35
city: STUTTGART
postcode: 70174
website: www.steinbeis-europa.de

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Germany [DE]
 Total cost 7˙992˙471 €
 EC max contribution 7˙992˙471 € (100%)
 Programme 1. H2020-EU.2.1.3. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Advanced materials)
 Code Call H2020-NMBP-2017-two-stage
 Funding Scheme /RIA
 Starting year 2018
 Duration (year-month-day) from 2018-01-01   to  2021-12-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    STEINBEIS 2I GMBH DE (STUTTGART) coordinator 499˙625.00
2    PROTIP MEDICAL FR (STRASBOURG) participant 961˙000.00
3    COMMISSARIAT A L ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES FR (PARIS 15) participant 754˙261.00
4    THE UNIVERSITY OF NOTTINGHAM UK (NOTTINGHAM) participant 708˙756.00
5    Steinbeis Advanced Risk Technologies GmbH DE (STUTTGART) participant 587˙500.00
6    AGENCIA ESTATAL CONSEJO SUPERIOR DEINVESTIGACIONES CIENTIFICAS ES (MADRID) participant 554˙763.00
7    INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE FR (PARIS) participant 499˙662.00
8    ELVESYS SAS FR (PARIS) participant 406˙875.00
9    AALTO KORKEAKOULUSAATIO SR FI (ESPOO) participant 401˙990.00
10    PROTOBIOS OU EE (TALLINN) participant 400˙000.00
11    CENTRE HOSPITALIER UNIVERSITAIRE DE LIEGE BE (LIEGE) participant 399˙637.00
12    DUBLIN CITY UNIVERSITY IE (DUBLIN) participant 392˙962.00
13    TURGUT OZAL EDUCATION SHA AL (TIRANA) participant 321˙375.00
14    DOLMEN DESIGN AND INNOVATION LIMITED IE (DUBLIN) participant 319˙375.00
15    STREINBEIS ADVANCED RISK TECHNOLOGIES INSTITUTE DOO KRAGUJEVAC RS (KRAGUJEVAC) participant 310˙000.00
16    BIODEVICE SYSTEMS SRO CZ (PRAHA) participant 296˙875.00
17    PRO-ACTIVE BE (BRUXELLES) participant 177˙812.00

Mappa

 Project objective

PANBioRA aims at providing a comprehensive solution for the time- and cost-effective risk assessment of i) new biomaterials under health or disease states or ii) a given biomaterial for each patient in a personalized manner. It will standardize the evaluation of biomaterials and open the venue for pre-implantation, personalized diagnostics for biomaterial based applications. PANBioRA will provide a modular platform to assess risks at different aspects and length scales. This comprises antibody response, cytotoxicity/genotoxicity at cell level, systemic and local effects at tissue and connected tissues (organ-on-a-chip) level. Moreover, physicochemical and biomechanical characterisation as well as predictive modelling at systems level will complement the system. This will be achieved by connecting testing modules in a structure supported by web-based modelling and risk radar tools together with a biomechanical testing system. The platform will incorporate standardized protocols yielding significantly more information than the current methods for biomaterial risk assessment. Its accuracy will be demonstrated using known reference materials and validated in a pre-clinical setting. PANBioRA will for the first time, predict the patient specific response to a given biomaterial before its implantation. This measure will allow for the selection of the best suitable material, minimizing side effects and improving health outcomes. It will also accelerate the process of validation of the biocompatibility of new devices by providing an automated, comprehensive process for the parallel assessment of risks at different scales aiding new biomaterial discovery and commercialisation. Altogether, PANBioRA will lead to a substantial economic impact due to a reduction of the amount of tests, decrease in healthcare costs due to complications. It will provide the necessary tools proper risk management related to biomaterials.

 Work performed, outcomes and results:  advancements report(s) 

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "PANBIORA" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "PANBIORA" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.2.1.3.)

DACOMAT (2018)

Damage Controlled Composite Materials

Read More  

ReSHEALience (2018)

Rethinking coastal defence and Green-Energy Service infrastructures through enHancEd-durAbiLIty high-performance fiber reinforced cement-based materials.

Read More  

BIORIMA (2017)

BIOmaterial RIsk MAnagement

Read More